<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain><z:hpo ids='HP_0002863'>Myelodysplastic syndromes</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>) are characterized by refractory cytopenias due to ineffective hematopoiesis in the marrow </plain></SENT>
<SENT sid="1" pm="."><plain>Cytokines play an important role in the regulation of hematopoiesis; dysregulation of their levels can lead to hematopoietic failure </plain></SENT>
<SENT sid="2" pm="."><plain>Considerable evidence implicates <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> <z:mp ids='MP_0001651'>necrosis</z:mp> factor alpha, transforming growth factor beta, interferons, interleukin 1beta, vascular endothelial growth factor (VEGF), and other inhibitory cytokines in the pathogenesis of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> </plain></SENT>
<SENT sid="3" pm="."><plain>These cytokines are produced by the interactions between the <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> clone and the bone marrow microenvironment </plain></SENT>
<SENT sid="4" pm="."><plain>Therapeutic strategies therefore may augment the action of stimulatory growth factors or disrupt the effects of myelosuppressive cytokines </plain></SENT>
<SENT sid="5" pm="."><plain>Erythropoietin alone and in combination with low-dose granulocyte colony-stimulating factor can lead to erythroid responses in selected patients </plain></SENT>
<SENT sid="6" pm="."><plain>Agents targeting inhibitory cytokines include thalidomide, lenalidomide, etanercept, infliximab, VEGF receptor inhibitor PTK-787, antithymocyte globulin, and SCIO-469, a p38 <z:chebi fb="0" ids="52290">mitogen</z:chebi>-activated <z:chebi fb="0" ids="37699">protein kinase inhibitor</z:chebi> </plain></SENT>
<SENT sid="7" pm="."><plain>Given the biologic <z:hpo ids='HP_0001425'>heterogeneity</z:hpo> of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>, no single treatment is effective for <z:hpo ids='HP_0000001'>all</z:hpo> patients with the disease </plain></SENT>
<SENT sid="8" pm="."><plain>With more detailed knowledge of cytokine signaling cascades, coupled with technological improvements in genomics and proteomics, the future treatment of this challenging disease may lie in combination therapies customized for relevant biologic effectors </plain></SENT>
</text></document>